SCHEMBL23780909

SCHEMBL23780909

COc1cc(F)ccc1C(O)c1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.44
SYK P43405 2/20 0.43
MAPT P10636 2/20 0.42
KAT7 O95251 1/20 0.40
KAT6A Q92794 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPC1 O15118 2/20 0.38
GAA P10253 2/20 0.38
RAB9A P51151 2/20 0.38
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPK1 P28482 1/20 0.38
CHRNA7 P36544 1/20 0.38
KCNH2 Q12809 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRM4 Q14833 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11398150 0.87 ACHE (0.51) ACHEMAPTKAT7KAT6ATDP1
SCHEMBL30616709 0.84 ACHE (0.44) ACHESYKMAPTKAT6AL3MBTL1
SCHEMBL23293462 0.84 ACHE (0.44) ACHESYKMAPTKAT6AL3MBTL1
SCHEMBL5655536 0.83 MAPT (0.42) ACHESYKMAPTKAT7KAT6A
SCHEMBL23748188 0.81 MAPT (0.41) MAPTL3MBTL1NPC1GAARAB9A
SCHEMBL23293136 0.80 KDM4E (0.39) ACHEMAPTGAAMEN1KMT2A
SCHEMBL22426192 0.80 MAPT (0.46) MAPTL3MBTL1TDP1TP53SMN1; SMN2
SCHEMBL5655395 0.78 ALDH1A1 (0.48) MAPTL3MBTL1TDP1NPC1RAB9A
SCHEMBL1632053 0.78 MAPT (0.47) MAPTKDM4EKCNH2CD74MIF
SCHEMBL30212038 0.77 CYP3A4 (0.42) ACHEMAPTKAT7KAT6ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866430-B2 Naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-09 US disclosed
US-20210277004-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2021-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866430-B2 Naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG ACHE 3792/4885SYK 697/4885MAPT 4477/4885
US-20210277004-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG ACHE 3792/4885SYK 697/4885MAPT 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.